Hyperphosphatemia Therapeutics Market Unlocking Growth Opportunities: Analysis and Forecast 2024-2032

Key Insights

The Hyperphosphatemia Therapeutics Market size was valued at USD 1.23 USD billion in 2023 and is projected to reach USD 2.14 USD billion by 2032, exhibiting a CAGR of 8.2 % during the forecast period. The set of treatments that aims to achieve lowering elevated blood levels of phosphate is called hyperphosphatemia therapeutics. To control phosphate levels, more frequently, phosphate binders that block the intestinal absorption of phosphate from the diet are employed, and for more advanced stages of the condition, dialysis which serves to remove phosphate is employed. Non-calcium-based binders which include Sevelamer and Lanthanum carbonate are with better features over Traditional Ca-based binders in that they are more likely to prevent vascular calcification. Beyond this, phosphate-restricted dietary regimens and vitamin D analogs could be applied as alternative management approaches. These drugs are therefore at the very core of the optimization of conditions such as chronic kidney disease, where phosphate levels could be one of the most important factors that lead to complications like vascular calcification and it may trigger the progression of cardiovascular disease. The impact of these findings is not just limited to the management of disorders such as kidney injury; they can also be useful in the treatment of other phosphate metabolism-related disorders, as well as improving the overall outcome and quality of life for the patient.

Hyperphosphatemia Therapeutics Trends

• Increasing prevalence of chronic kidney disease (CKD)
• Growing demand for effective phosphate binders
• Rising awareness of the importance of phosphate management in CKD
• Development of new and innovative phosphate binders

Driving Forces: What's Propelling the Hyperphosphatemia Therapeutics Market

• Increasing prevalence of chronic kidney disease (CKD): CKD is a major risk factor for the development of hyperphosphatemia. The number of people with CKD is expected to increase over the next decade, due to factors such as the aging population and the increasing prevalence of diabetes and obesity.
• Growing demand for effective phosphate binders: Phosphate binders are medications that help to lower phosphate levels in the blood. The demand for effective phosphate binders is growing, as the number of people with CKD increases.
• Rising awareness of the importance of phosphate management in CKD: The importance of phosphate management in CKD is becoming increasingly recognized by healthcare professionals. This is leading to a greater demand for phosphate binders.
• Development of new and innovative phosphate binders: New and innovative phosphate binders are being developed that are more effective and have fewer side effects. This is expected to further drive the growth of the market.

Challenges and Restraints in Hyperphosphatemia Therapeutics Market

• Side effects of phosphate binders: Phosphate binders can cause side effects, such as gastrointestinal upset, nausea, and vomiting. This can limit their use in some patients.
• Cost of phosphate binders: Phosphate binders can be expensive, which can limit their use in some patients.
• Lack of awareness of hyperphosphatemia: Many people with CKD are not aware of the importance of phosphate management. This can lead to delayed diagnosis and treatment of hyperphosphatemia.

Emerging Trends in Hyperphosphatemia Therapeutics

• Development of new phosphate binders with fewer side effects: New phosphate binders are being developed that have fewer side effects, such as gastrointestinal upset, nausea, and vomiting. This is expected to increase the use of phosphate binders in patients with CKD.
• Use of phosphate binders in combination with other therapies: Phosphate binders are often used in combination with other therapies, such as dialysis, to lower phosphate levels in the blood. This is expected to increase the demand for phosphate binders.
• Growing use of phosphate binders in home dialysis: Phosphate binders are increasingly being used in home dialysis. This is expected to further drive the growth of the market.

Growth Catalysts in the Hyperphosphatemia Therapeutics Industry

• Increasing prevalence of chronic kidney disease (CKD)
• Growing demand for effective phosphate binders
• Rising awareness of the importance of phosphate management in CKD
• Development of new and innovative phosphate binders
• Use of phosphate binders in combination with other therapies
• Growing use of phosphate binders in home dialysis

Market Segmentation: Hyperphosphatemia Therapeutics Analysis

The global hyperphosphatemia therapeutics market is segmented by drug class, distribution channel, and region.

By drug class, the market is segmented into:

• Sevelamer
• Calcium-based phosphate binders
• Lanthanum carbonate
• Iron-based phosphate binders
• Others

By distribution channel, the market is segmented into:

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Leading Players in the Hyperphosphatemia Therapeutics Market

• Sanofi (France) 
• Takeda Pharmaceutical Company Limited (Japan)
• Lupin (India) 
• Astellas Pharma Inc. (Japan)
• Akebia Therapeutics, Inc. (U.S.)
• CSL (Australia) 
• Ardelyx (U.S.) 
• Unicycive (U.S.)

Significant Developments in Hyperphosphatemia Therapeutics Sector

Some of the significant developments in the global hyperphosphatemia therapeutics market include:

August 2023 - Astellas Pharma Inc. collaborated with DivcoWest, a DivCore Capital Company. The collaboration planned to open a new life science facility for Astellas at Morgan Avenue in Cambridge.

July 2023 – Ardelyx received approval to use Tenapanor as a treatment for hyperphosphatemia in China. This approval aided the company in expanding its geographical presence in the international market.

May 2023 – CSL Vifor announced the recommendation of England's National Institute for Health and Care Excellence (NICE) for Kapruvia as a treatment for moderate-to-severe CKD.

October 2022 – Ardelyx’s partner Kyowa Kirin, Co. Ltd. (KKC) submitted a new drug application to the Japanese Ministry of Health, Labour and Welfare for tenapanor. This drug can contribute to the company’s revenue growth if approved.

December 2020 – Unicycive collaborated with Spectrum Pharmaceuticals. The collaboration aimed to sign a licensing agreement for Renazorb (lanthanum polycarbonate), a late-stage medicine for treating hyperphosphatemia.

Comprehensive Coverage Hyperphosphatemia Therapeutics Market Report

Our comprehensive market report provides an in-depth analysis of the global hyperphosphatemia therapeutics market. The report covers the following aspects:

• Market Size and Growth Forecasts
• Market segmentation and analysis
• Competitive landscape
• Market drivers and challenges
• Emerging trends and growth opportunities
• Strategic recommendations for market participants